The Federal Government of Nigeria has granted provisional approval for the R21/Matrix malaria vaccine developed by scientists at Oxford University.
Director-General of the National Agency for Food and Drug Administration And Control (NAFDAC), Mojisola Adeyeye, announced this on Monday at a press conference in Abuja.
She said, “The National Agency for Food and Drug Administration and Control (NAFDAC) in exercising its mandate as stipulated by its enabling law, NAFDAC Act CapN1, LFN 2004 is granting registration approval for R21 malaria vaccine.
“The vaccine is indicated for prevention of clinical malaria in children from five months to 36 months of age. The storage temperature of the vaccine is 2-8 °C.”
According to Adeyeye, NAFDAC received the dossier of the R21 and subjected it to independent review by experts from Nigeria’s tertiary institutions and the agency’s in-house vaccine review committee.
The director-general said a joint review was then called after the team assessed the vaccine as “adequate” and the in-house committee also assessed it as “satisfactory”.
She explained further:
“A provisional approval of the R21 malaria vaccine was recommended and this shall be done in line with the WHO’s malaria vaccine implementation guideline.
“While granting the approval, the agency has also communicated the need for expansion of the clinical trial conducted to include a phase 4 clinical trial/pharmacovigilance study to be carried out in Nigeria.
“The brief on the approval of the R21 Malaria vaccine has been communicated to the minister of health and national primary health care development agency for appropriate actions toward immunisation in the respective population.”
